Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.69	$1.75	$1.41 ▼ $5.01	$9.84M	1.29	63,785 shs	17,463 shs
ATNF 180 Life Sciences	$7.04 -7.5%	$2.27	$0.66 ▼ $17.75	$45.96M	0.38	21.61 million shs	11.35 million shs
BTAI BioXcel Therapeutics	$5.48 +15.4%	$2.35	$1.17 ▼ $13.36	$28.77M	0.05	22.21 million shs	8.78 million shs
ENLV Enlivex Therapeutics	$1.82 +2.2%	$1.25	$0.81 ▼ $2.10	$42.10M	0.8	444,911 shs	2.24 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-1.17%	+2.42%	+3.68%	-9.14%	-48.00%
ATNF 180 Life Sciences	-28.88%	+121.87%	+751.14%	+544.92%	+312.02%
BTAI BioXcel Therapeutics	-15.18%	+39.30%	+150.00%	+227.59%	-56.28%
ENLV Enlivex Therapeutics	+14.10%	+31.85%	+44.72%	+78.00%	+42.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.5985 of 5 stars	3.5	5.0	0.0	3.3	0.8	1.3
ATNF 180 Life Sciences	0.5061 of 5 stars	0.0	2.0	0.0	3.0	1.7	0.0
BTAI BioXcel Therapeutics	4.5335 of 5 stars	3.4	5.0	4.5	2.8	1.7	0.6
ENLV Enlivex Therapeutics	3.3352 of 5 stars	3.7	5.0	0.0	3.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	817.16% Upside
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
BTAI BioXcel Therapeutics	2.80	Moderate Buy	$39.75	625.36% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	449.45% Upside

Current Analyst Ratings Breakdown

Latest APRE, ENLV, ATNF, and BTAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/14/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/12/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.57	N/A	N/A	$2.30 per share	0.73
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$0.89 per share	N/A
BTAI BioXcel Therapeutics	$2.27M	14.63	N/A	N/A	($17.78) per share	-0.31
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.32	N/A	N/A	N/A	-1,645.01%	-78.90%	-62.67%	N/A
ATNF 180 Life Sciences	-$6.17M	-$15.07	N/A	∞	N/A	N/A	-141.25%	-80.77%	N/A
BTAI BioXcel Therapeutics	-$59.60M	-$12.64	N/A	N/A	N/A	-5,869.82%	N/A	-134.45%	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)

Latest APRE, ENLV, ATNF, and BTAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	-$0.53	+$0.24	-$0.53	N/A	$0.12 million
8/12/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	-$2.45	-$0.15	-$2.45	$0.21 million	$0.12 million
7/23/2025	Q2 2025	ATNF 180 Life Sciences	N/A	-$0.30	N/A	-$0.30	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/15/2025	Q1 2025	ATNF 180 Life Sciences	N/A	-$0.67	N/A	-$0.67	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.34	5.90
ATNF 180 Life Sciences	N/A	0.58	0.58
BTAI BioXcel Therapeutics	N/A	0.76	1.45
ENLV Enlivex Therapeutics	N/A	7.20	7.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
ATNF 180 Life Sciences	4.07%
BTAI BioXcel Therapeutics	30.68%
ENLV Enlivex Therapeutics	1.02%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
ATNF 180 Life Sciences	38.20%
BTAI BioXcel Therapeutics	21.20%
ENLV Enlivex Therapeutics	12.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.83 million	5.03 million	No Data
ATNF 180 Life Sciences	7	6.04 million	3.73 million	No Data
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable

APRE, ENLV, ATNF, and BTAI Headlines

Recent News About These Companies

Enlivex to Present Key Results from Osteoarthritis Trial

August 14 at 1:16 PM | msn.com

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

August 14 at 8:30 AM | globenewswire.com

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

July 28, 2025 | globenewswire.com

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 13, 2025 | usatoday.com

Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona

June 11, 2025 | nasdaq.com

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

June 10, 2025 | globenewswire.com

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025 | globenewswire.com

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

April 23, 2025 | globenewswire.com

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial

April 23, 2025 | msn.com

Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis

April 23, 2025 | nasdaq.com

Enlivex completed enrollment of patients in Phase II trial of Allocetra

April 22, 2025 | markets.businessinsider.com

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

April 21, 2025 | globenewswire.com

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?

April 7, 2025 | finance.yahoo.com

Enlivex Therapeutics doses first patient in Phase I trial of Allocetra

April 4, 2025 | markets.businessinsider.com

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

April 3, 2025 | globenewswire.com

Enlivex Therapeutics Releases 2024 Financial Statements

March 31, 2025 | tipranks.com

Enlivex Therapeutics price target raised to $7 from $6 at H.C. Wainwright

March 24, 2025 | markets.businessinsider.com

Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis

March 19, 2025 | nasdaq.com

Enlivex to receive Chinese patent for use of Allocetra as a potential treatment in patients with osteoarthritis

March 19, 2025 | pharmabiz.comP

Enlivex Therapeutics receives notice of allowance for Chinese patent

March 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, ENLV, ATNF, and BTAI Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.69 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$1.74 +0.05 (+2.72%)

As of 07:39 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

180 Life Sciences NASDAQ:ATNF

$7.04 -0.57 (-7.49%)

Closing price 04:00 PM Eastern

Extended Trading

$7.27 +0.23 (+3.27%)

As of 08:00 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

BioXcel Therapeutics NASDAQ:BTAI

$5.48 +0.73 (+15.37%)

Closing price 04:00 PM Eastern

Extended Trading

$6.13 +0.65 (+11.86%)

As of 08:00 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Enlivex Therapeutics NASDAQ:ENLV

$1.82 +0.04 (+2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.93 +0.11 (+6.04%)

As of 07:58 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time